Brief: CARsgen Therapeutics Says CT041 Granted Prime Eligibility By EMA For Treatment Of Gastric/Gastroesophageal Junction Cancer
15/11/2021 01:58
Nov 15 (Reuters) - CARsgen Therapeutics Holdings Ltd
2171.HK :
* CT041 GRANTED PRIME ELIGIBILITY BY EMA FOR TREATMENT OF
GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER
Source text for Eikon: ID:nHKS3cTnxZ
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer